Assistant Professor, Radiation Oncology, Ohio State University College of Medicine
Radiation Oncology
Dr. Meng Welliver, MD
|
|
Give Review
Doctor Meng Welliver, MD is an expert in the field of Radiation Oncology. He graduated from Penn State College of Medicine. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Meng Welliver is a published MD. He has 24 papers published. The most current publication "Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.
- Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.
- Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy.
- The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation.
- The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients wit...
- Dosimetric consequences of pancreatic tumor motion when predetermined treatment margins are employed during intensity-modulated radiation therapy.
- SU-E-T-436: Feasibility of Using the 'Irregular Surface Compensator' Planning Feature of the Eclipse TPS for Total Body Irradiation (TBI) Treatment Planning.
- Down-regulation of survivin and hypoxia-inducible factor-1 alpha by beta-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft.
- The role of p53 in base excision repair following genotoxic stress.
- The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation.
- Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide.
- Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase.
- Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine.
- Point mutations at multiple sites including highly conserved amino acids maintain activity, but render O6-alkylguanine-DNA alkyltransferase insensitive to O6-benzylgua...
- Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA al...
- Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic s...
- The role of human O(6)-alkylguanine-DNA alkyltransferase in promoting 1,2-dibromoethane-induced genotoxicity in Escherichia coli.
- Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
- Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
- Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O...
- Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine.
- Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine.
- Improving Intra-Fractional Target Position Accuracy Using a 3D Surface Surrogate for Left Breast Irradiation Using the Respiratory-Gated Deep-Inspiration Breath-Hold T...
Schools
Pa State Univ Coll Of Med
Doctors Specialties
- Radiation Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Pennsylvania Health System -
Penn State College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1053476283 | |
| NPPES Provider LastName | WELLIVER | |
| NPPES Provider FirstName | MENG | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 26.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1053476283 |
| Last Name Of The Provider | WELLIVER |
| First Name Of The Provider | MENG |
| View All |
Similar Doctors
|
|
Dr. John C. Grecula, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Virginia M. Diavolitsis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jose A. Bazan, DO
This Doctor is OpenDoctor Recommended.
|
|
Dr. Douglas D. Martin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric C. Allan, MD |
|
|
Dr. Eric D. Miller, MD |
|
Dr. Simon S. Lo, MD |